Founded in 1987, MEBO's medical research is supported with over 3500 published clinical papers on Moist Exposed Burn Ointment.

MEBO's international head office is based in Los Angeles, California, U.S.A. The group holds more than 20 patents in the US, Canada, Europe, Japan, and China for cell and organ regeneration.

MEBO's manufacturing sites include China and the United Arab Emirates. All facilities are certified with Good Manufacturing Practice certification (GMP).

The MEBO International Group's research focuses on the applications of stem cell and regenerative medicine, potentiating and stimulating stem cells in situ, directly repairing and regenerating skin tissue without the need for skin transplants. This is the only medical institution in the world to successfully regenerate and repair tissue in vitro (outside the body) and in situ (inside the body).

The company has received many international acknowledgments for research and success in burn wound therapy, including:

The Award of Achievement for Elite (UAE); 2000
The D'Honneur Exceptional, France; 1992
The States Outstanding Contributing Scientist of China; 1992
The American Burns Victim Society's Humanitarian Prize; 1993
More recently, in 2013, Professor Xu, founder of The MEBO International Group, was awarded The Golden Biatec Award, for his contribution to the wellbeing of the world population through his most recent US patent, 'Damaged Organ Regeneration'.


The regenerative life science and technology is the development priority of MEBO International. The technology and products for the regenerative restoration of gastrointestinal (GI) organs have been applied in the market for many years, which has realized the GI mucosal renewal, in situ regeneration of ulcerative GI mucosa, regenerative restoration and rejuvenation of senescent gastrointestinal organs, prevention of refractory GI diseases and regeneration of GI organs afflicted with refractory GI diseases, in a large sample population, and thus a GI health care system has been established for the normal general population and MEBO International is constructing the transnational high-end marketing system for its GI regenerative nutritional substance. Furthermore, MEBO Group has an independent tissue engineering research system for regenerative medical devices, which has accomplished the research on human body biomedical materials, bio-substitute materials for human body tissue engineering products, and now the system is expanding its influence nationwide based on the mature domestic market of regenerative medical technology.